Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $2.1 million.

  • BioLineRx's Other Accumulated Expenses fell 3688.43% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 3688.43%. This contributed to the annual value of $3.1 million for FY2024, which is 662.09% down from last year.
  • Per BioLineRx's latest filing, its Other Accumulated Expenses stood at $2.1 million for Q3 2025, which was down 3688.43% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Other Accumulated Expenses peaked at $3.4 million during Q3 2024, and registered a low of $1.8 million during Q1 2025.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $2.5 million (2024), whereas its average is $2.6 million.
  • Per our database at Business Quant, BioLineRx's Other Accumulated Expenses skyrocketed by 2560.57% in 2024 and then crashed by 3688.43% in 2025.
  • Over the past 3 years, BioLineRx's Other Accumulated Expenses (Quarter) stood at $3.4 million in 2023, then fell by 6.62% to $3.1 million in 2024, then plummeted by 32.07% to $2.1 million in 2025.
  • Its Other Accumulated Expenses stands at $2.1 million for Q3 2025, versus $2.8 million for Q2 2025 and $1.8 million for Q1 2025.